<DOC>
	<DOCNO>NCT01109485</DOCNO>
	<brief_summary>The objective study evaluate safety Olopatadine Ophthalmic Solution 0.1 % Japanese child allergic conjunctivitis .</brief_summary>
	<brief_title>Clinical Evaluation 0.1 % Olopatadine Hydrochloride Ophthalmic Solution Pediatric Patients</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Olopatadine Hydrochloride</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Patients whose parent guardians issue inform consent Patients age 7 less 16 baseline Patients confirm show type I allergy Patients allergic conjunctivitis Patients subjective symptom baseline ( itch sensation , foreign body sensation , eye pain , etc . ) Patients ocular itch sensation injection cause disease allergic conjunctivitis Patients retinal detachment , diabetic retinopathy progressive retinal disease Patients history ocular infection , corneal herpes relapse corneal erosion sudden onset secondary corneal injury Patients receive continuous treatment corticosteroid within 3 month Patients receive immunotherapy Patients require continuous treatment corticosteroid , immunosuppressor , nonsteroidal antiinflammatory agent , vasoconstrictor , antihistamine , antiallergy agent , herbal preparation indicate `` conjunctivitis '' ophthalmic solution test product Patients undergone ocular laser therapy within 3 month Unilaterally blind patient ( best correct visual acuity : 0.01 ) Patients history allergy hypersensitivity olopatadine hydrochloride Patients necessitating use contact lens study period Other patient judge attend physician inappropriate study</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Allergic conjunctivitis</keyword>
</DOC>